fda compounding semaglutide enforcement november 2025 Compounded Semaglutide: Safety & Regulation Guide

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

22.22

★★★★☆4.8 (126)

FDA Warns on Certain Forms of Compounded Semaglutide

28.59

★★★★★4.9 (98)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

27.19

★★★★★5.0 (157)

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

21.82

★★★★★4.7 (84)

How FDA Crackdowns Are Affecting GLP-1 Use In 2025

27.81

★★★★★4.9 (203)

Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP-1s and peptides, you've probably noticed something. The FDA is paying

27.94

★★★★★5.0 (176)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

22.98

★★★★★4.8 (132)